Genetic disorders occur due to alterations in the primary genetic material—deoxyribonucleic acid (DNA)—of an organism.

MGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing MG29-1 nuclease targeting the albumin safe harbor locus showed no evidence of ...

CRISPR–Cas9-based therapies are widely investigated for their clinical applications. However, there are limitations ...

Existing gene-editing technologies have led to significant advances in both medicine and food production. However, momentum appears to be slowing, particularly in health applications, as early hype is ...

CHANGE-seq-BE was developed to enable scientists to better understand base editors, an important class of CRISPR precise genome editors.

This study is led by Professor Yongming Wang's research team from Fudan University, in collaboration with the team led by Professor Renjie Chai from Southeast University. This study is published in a ...

CRISPR-Cas gene editing has transformed research and industry, enabling precise genome modification for diverse applications, including therapeutic development. However, this method is not without ...

Scientists and physicians can better assess precision genome editing technology using a new method made public today by St. Jude Children's Research Hospital. Significant amounts of time and resources ...

Qi Biodesign, a company involved in genome-editing technologies, announced that it has completed a $75 million funding round, which includes seed funding and Series Pre-A and Series A stages. Beijing ...

Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived toolbox. Metagenomi is ...